Replies to post #215219 on Biotech Values

[dangerM]

ACHN/JNJ study names

... I am not sure, but they had several ph II trials. The results in april were from the "604" study in which they also refer to the omega trial (then being enrolled but with results expected later).

I guess (if they don't sell a block to a private investor) JNJ will simply opportunistically sell into any stock price increase from January onwards.

http://ir.achillion.com/releasedetail.cfm?releaseid=1022374

Ongoing Phase 2b Triple Combination Development Program

Janssen has initiated a multi-center, randomized, open-label Phase 2b study of JNJ-4178, the triple combination of once-daily odalasvir 25mg, AL-335 800mg, and simeprevir 75mg for treatment durations of six and eight weeks. Designated OMEGA-1, this trial has now completed enrollment of more than 365 treatment-naïve and treatment-experienced, non-cirrhotic patients chronically infected with HCV genotype 1,2,4,5 and 6. Results from this trial are anticipated during the second half of 2017. In addition, the ‘604 Study' is ongoing and will assess the triple combination JNJ-4178 in patients with compensated cirrhosis.

P.S.: to some part me wonders inhowfar yesterday's sell off was panicking or algos (as far as I understand they formally had to file a prospectus to register JNJ's shares for trading ... not dilution, but as you wrote some lid on the stock price)